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Colorectal  cancer  is  the  third  most  common  cancer,  with  recent  advances  in  the management  of  unre-
sectable  metastatic  lesions.  The aim  of  this  review  is  to discuss  the  remaining  options  for  heavily
pretreated  patients  with  unresectable  metastatic  colorectal  cancer.  Beyond  second-line  treatment,  two
epidermal  growth  factor  receptor  (EGFR)  inhibitors,  cetuximab  and panitumumab,  have  a demonstrated
clinical  interest  in  patients  with  KRAS  wild-type  tumours.  However,  few  data  exist  in  patients  pretreated
with  an  anti-EFGR  and  who  are  being  rechallenged  with anti-EGFR  drugs.  Reintroduction  of  chemother-
apy  should  be considered.  In September  2012,  regorafenib,  a  multi-kinase  inhibitor  was  approved  by the
US  Federal  Drug  Administration  for patients  refractory  to other  standard  treatments.  In the  case  of  metas-
tases  limited  to the  liver,  transarterial  chemoembolization,  hepatic  artery  infusion  and  radioembolizationultiline strategy could  also be discussed  in selected  patients.  With  the  multiplication  of  therapeutic  options  in  ﬁrst-line,
second-line  treatment,  and  beyond,  the  concept  of  subsequent  lines  of  chemotherapy  should  be  replaced
by  a  multiline  strategy,  dependent  on the  patient  and  on tumour  biology.  A better understanding  of  the
tumour  biology  and  predictive  factors  for  the  response  to these  therapies  is  needed,  and  further  strategic
trials  are  urgently  warranted.
© 2013 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica. Introduction
Colorectal cancer is the third most commonly diagnosed
ancer with around 1 million new cases and more than 500,000
eaths every year worldwide [1]. Patients with advanced and
nresectable disease can be eligible for multiple lines of treatment.
hree major chemotherapeutic agents (5-ﬂuorouracil (5-FU),
rinotecan and oxaliplatin), one anti-vascular endothelial growth
actor (anti-VEGF, bevacizumab) and two epidermal growth factor
eceptor inhibitors (cetuximab and panitumumab) have shown
ell-demonstrated clinical activity for the treatment of metastatic
olorectal cancer. Most patients can receive the three chemothera-
eutic agents during their ﬁrst two lines of treatment [2]. Moreover,
he simultaneous administration of ﬂuorouracil, oxaliplatin and
rinotecan in ﬁrst-line treatment showed better antitumoural
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activity than a doublet regimen [3]. Phase III trials reported the
efﬁcacy of bevacizumab in the ﬁrst or second line [4–6], but there
are no data supporting its prescription beyond the second line.
Anti-epidermal growth factor receptor drugs (cetuximab, pani-
tumumab) demonstrated clinical activity in third-line treatment,
but can also be recommended in ﬁrst- and second-line treatment
[7,8]. The use of cetuximab in colorectal cancer has recently been
reviewed [9,10].
In  case of disease progression after two lines of treatment,
the survival is about 4–6 months with best supportive care (BSC)
alone [11,12]. However, some patients are still able and willing
to receive further therapy. While all major therapeutic agents can
be recommended in ﬁrst- and second-line treatment, what are
the remaining options for third-line treatment and beyond? The
aim of this review is to highlight the current therapeutic options
for patients progressing after two lines of therapy for metastatic
unresectable colorectal cancer.
2. Chemotherapy can still be an option
2.1. Strategic trials investigating third-line therapy
Open access under CC BY-NC-ND license.Median overall survival depends on patients’ access to the
three major chemotherapy agents (ﬂuorouracil, irinotecan and
oxaliplatin) [13]. All three agents are often administered in
erologica Italiana S.r.l. Open access under CC BY-NC-ND license.
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Table 1
Strategic trials with a third-line treatment planned in the protocol.
FFCD 2000–2005 [34] CAIRO [33]
Groups Sequential treatment Combined treatment Sequential treatment Combined treatment
1st line: LV5FU2 1st line: FOLFOX 6 1st line: Capecitabine 1st line: CAPIRI
2nd line: FOLFOX 6 2nd line: FOLFIRI 2nd line: irinotecan 2nd line: CAPOX
3rd line: FOLFIRI 3rd line: Capecitabine, LV5FU2 or other 3rd line: CAPOX No third-line
Number  of patients 205 205 p 401 402 p
Overall survival
(months [95% CI])
16.4  [14.5–18.6] 16.2 [14.4–18.4] 0.85 16.3 [14.3–18.1] 17.4 [15.2–19.2] 0.3281
Progression  free
survival  in third line
13.2  [11.7–14.3] 12.9 [11.9–14.4] 0.62 10.3 [9–11.1] – –
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Overall  response rate
(%  [95% CI])
8 [3–13] 9 [3–15] 
rst- and second-line treatment with doublet regimens or even
n ﬁrst-line treatment with triplet regimens. The third-line ther-
py can be anticipated in a multiline therapeutic strategy (Table 1).
 strategic trial on 820 patients evaluated a sequential treat-
ent with capecitabine in ﬁrst-line, irinotecan in second-line and
apecitabine plus oxaliplatin in third-line treatment versus an
p-front combined therapy with capecitabine plus irinotecan in
rst-line and capecitabine plus oxaliplatin in second-line treat-
ents [14]. The median overall survival of the two  groups did not
iffer, but only 36% of patients in the sequential group received a
hird-line treatment, and the rate of patients who received a third-
ine treatment not planned in the protocol in the combination group
as not speciﬁed. The FFCD 2000–05 trial included 410 patients
ho were randomized to receive either sequential chemotherapy
LV5FU2 then FOLFOX 6 then FOLFIRI then any fourth-line therapy)
r combined chemotherapy (FOLFOX 6 then FOLFIRI then any third-
nd fourth-line therapies at the investigator’s discretion). Fifty-
ve percent of patients received the planned third-line treatment
n the sequential arm and 44% of patients received any third-line
reatment in the combined arm. In the third-line treatment, dis-
ase control and response rate were 47% and 8% respectively with
OLFIRI in the sequential arm, and 24% and 9% in the combined
rm. The overall survival in the two groups did not differ sig-
iﬁcantly (16.4 months in the sequential arm versus 16.2 in the
ombination arm, P = 0.85) [15]. In these trials, the median overall
urvival from ﬁrst-line treatment is low, probably because these
tudies were conducted before the use of targeted therapies. If the
equential strategy is chosen, the question on the third-line treat-
ent is easier, as every patient with metastatic colorectal cancer
ith good performance status should receive both oxaliplatin and
rinotecan. Some patients can receive a triple chemotherapy regi-
en  as the ﬁrst-line treatment. In this setting, to our knowledge,
o data have been published concerning a third-line therapy. The
trategy must be decided upon according to the patient’s symp-
oms and the objectives of the treatment. If there is hope of the
atient becoming eligible for surgery, a combination therapy with
 high expected response rate in front-line therapy should be rec-
mmended. However, in patients with advanced disease (multiple
etastases at different organ sites (liver, lungs, carcinomatosis),
ut few symptoms, a monochemotherapy with or without a mono-
lonal antibody could be appropriate [16].
.2. Fluorouracil or capecitabine beyond second-line treatment,
n  combination or as single agentsIn the FFCD 2000–05 trial, 44% of the patients receiving the
p-front combined strategy were treated with third-line therapy,
hich could be infusional 5-FU, capecitabine, or another drug.
here are few data on the effectiveness of 5FU or capecitabine as0.85 4 [1–9] – –
single  agents after the failure of 5FU-based doublet regimens. In a
study published in 2003, 463 patients progressing after ﬁrst-line
IFL therapy (irinotecan, bolus ﬂuorouracil and leucovorin) were
randomized to receive either LV5-FU2 or Folfox-4 regimens. For
patients treated with LV5-FU2, the response rate was 0%, and the
median time to progression was  2.7 months (95% conﬁdence inter-
val (CI) 1.8 to 3.0 months) [17]. Capecitabine is activated through
a three-step process into 5-FU, resulting in higher concentrations
of 5 FU in tumour cells compared with normal tissues. In preclin-
ical trials, responses to capecitabine in 5FU-resistant tumour cell
lines had been demonstrated [18]. A retrospective study included
20 patients with metastatic colorectal cancer to be treated with
third-line therapy, after progression on 5FU combinations with
oxaliplatin and irinotecan. With capecitabine in third-line treat-
ment, the response rate was  0%, and the time to progression was
2.8 months. The most common side effects were hand-foot syn-
drome and diarrhoea. One patient died due to febrile neutropaenia.
Capecitabine as a monotherapy did not provide any clinical ben-
eﬁt [19]. These data do not support the use of capecitabine or
5FU as single agents after the failure of doublet regimens. How-
ever, the use of capecitabine was investigated in combination
with other chemotherapy agents. Capecitabine requires thymidine
phosphorylase to metabolize to 5FU. Mitomycin C is an antitumour
antibiotic that induces upregulation of intratumoural thymidine
phosphorylase in vivo [20]. In third-line therapy, the combination
of capecitabine with mitomycin C has been investigated in phase II
studies. In a study including 21 patients, the response rate was 4.8%,
there was  19% stable disease, the progression-free survival was  2.6
months and the overall survival was  6.8 months [21]. Another study
gave more encouraging results. Thirty-ﬁve patients were included,
the response rate was  15.2%, 48.5% of patients had stable disease,
the progression-free survival was  5.4 months (95% CI 4.6 to 6.2),
the overall survival was 9.3 months (95% CI 6.9 to 11.7) [22].
2.3.  Oxaliplatin reintroduction
The  reintroduction of a previously used agent can be considered.
For patients treated by FOLFOX and FOLFIRI in ﬁrst- and second-
line therapy, the reintroduction of previously used chemotherapy
could be an option. The OPTIMOX trial randomly compared two
chemotherapy schedules in 620 patients. One group of patients
received a Folfox-4 regimen until progression, another group
received Folfox-7 for 6 cycles, followed by LV5FU for 12 cycles
and then planned Folfox-7 reintroduction. Progression-free sur-
vival and overall survival were similar in both groups. However,
oxaliplatin was reintroduced in only 40% of patients included in
the stop-and-go strategy [23]. Oxaliplatin reintroduction was  an
independent factor and had signiﬁcant impact on survival (Hazard
ratio (HR) = 0.51, 95% CI 0.3 to 0.9, P = 0.009) [24]. Three hundred and
d Live
t
s
i
t
h
a
o
m
f
f
l
p
i
o
O
t
n
p
t
s
t
2
t
l
a
l
h
v
p
c
b
o
i
a
c
r
1
1
s
1
a
c
h
H
o
i
m
4
i
a
w
a
t
w
o
v
l
t
e
t
a
cF. Foubert et al. / Digestive an
hirty patients were included in a study presented at the American
ociety of clinical oncology (ASCO) 2009 meeting. Patients had been
ncluded in OPTIMOX 1 and 2 studies, or had relapsed after metas-
ases surgery and neoadjuvant or adjuvant FOLFOX. All patients
ad been rechallenged with oxaliplatin. Progression-free survival
nd median overall survival were signiﬁcantly better when the
xaliplatin-free interval was more than 12 months (7.1 and 22.1
onths, respectively) versus 4.8 and 7.6 months for an oxaliplatin-
ree interval of between 6 and 12 months, and 4.8 and 7.6 months
or an interval of less than 6 months [25]. Reintroduction of oxalip-
atin in third-line therapy can therefore be an option for patients
reviously treated with this drug in ﬁrst- or second-line treatment,
n particular if oxaliplatin was stopped because of toxicity and if the
xaliplatin-free interval was long. It is important to note that the
PTIMOX study investigated a stop-and-go strategy. Reintroduc-
ion is then not a true different line of treatment. This study does
ot support the reintroduction of oxaliplatin in patients who have
rogressed under oxaliplatin. However, it highlights the impor-
ance of considering oxaliplatin reintroduction if the drug has been
topped as part of a stop-and-go strategy or because of temporary
oxicity.
.4. Anti-EGFR therapies: clinical activity beyond second-line
reatment
The  EGFR signalling pathway regulates cell differentiation, pro-
iferation, migration, angiogenesis and apoptosis. Cetuximab is
 chimeric monoclonal antibody that binds to the extracellu-
ar domain of EGFR to modulate tumour cell growth. Cetuximab
as been associated with improved overall survival (6.1 months
ersus 4.6 months, HR = 0.77; 95% CI 0.64 to 0.92; P = 0.005) and
rogression-free survival (HR = 0.68; 95% CI 0.57 to 0.80; P < 0.001)
ompared with best supportive care alone in a prospective study
ased on 572 patients previously treated with 5FU, irinotecan and
xaliplatin [11,26]. The BOND study randomized 329 patients with
rinotecan-refractory colorectal cancer into two groups (cetuximab
nd irinotecan or cetuximab monotherapy) and demonstrated efﬁ-
acy of cetuximab in combination with irinotecan, as the response
ate (22.9% [95% IC 17.5 to 29.1%] versus 10.8% [95% IC 5.7 to
8.1%], P = 0.007), the progression-free survival (4.1 months versus
.5 months, HR = 0.54; 95% CI 0.42 to 0.71; P < 0.001) and the overall
urvival (8.6 months versus 6.9 months, HR = 0.91; 95% CI 0.68 to
.21; P = 0.48) were higher in this group [27]. For these two  studies,
bout eighty percent of patients received two or more previous can-
er therapies before inclusion. Kirsten rat sarcoma 2 viral oncogene
omolog (KRAS) status was not determined in the BOND study.
ealth quality of life reports showed that the effect of cetuximab
n survival and progression-free survival (PFS) was associated with
mproved quality of life [28].
Panitumumab is a fully humanized anti-EGFR antibody. Panitu-
umab  was ﬁrst evaluated as a single agent for chemotherapy in
63 patients with refractory metastatic colorectal cancer random-
zed into two groups (panitumumab plus BSC versus BSC alone),
nd was associated with improved progression-free survival (8
eeks versus 7.3 weeks, HR = 0.54; 95% CI 0.44 to 0.66, P < 0.0001)
nd objective response rate (10% versus 0%, P < 0.0001) [12]. In
his phase III study, no signiﬁcant difference in overall survival
as observed (HR = 1.00; 95% CI 0.82 to 1.22), but the high rate
f crossover of the BSC patients could have biased the overall sur-
ival data. In the selected patients with wild-type KRAS tumours,
ower scores of deterioration in quality of life were observed in
he panitumumab group than in the BSC alone group. These scores
valuate the most important symptoms associated with colorec-
al cancer (including fatigue, pain, weight loss, nausea, diarrhoea,
bility to enjoy life and contentedness in quality of life) and less spe-
iﬁc dimensions such as mobility, self care, anxiety, and depression.r Disease 46 (2014) 105– 112 107
Patients  treated with panitumumab showed signiﬁcantly better
control of the symptoms, and better quality of life, despite skin
toxicity associated with panitumumab treatment [29]. The results
from clinical trials testing the effect of anti-EGFR antibodies in
third-line therapy are summarized in Table 2.
Many studies reported that the beneﬁts of anti-EGFR drugs are
limited to the patients with KRAS wild-type tumours. The role of
KRAS status as a strong predictive factor for cetuximab therapy
was ﬁrst retrospectively identiﬁed [30] and then conﬁrmed in fur-
ther large clinical trials [7,8,26,31–33]. As therapeutic beneﬁts are
limited to patients with wild-type KRAS tumours, it is now rec-
ommended that monoclonal antibody-mediated EGFR inhibition
should be limited to these patients only. Thirty to 45% of patients
have KRAS mutant tumours, and are not eligible for anti-EGFR
therapies [34]. The discordance of KRAS mutation between the pri-
mary tumour and distant metastases occurs in 5–10% of metastatic
colorectal cancers [35–37]. It could partly explain the lack of efﬁ-
ciency of anti-EGFR drugs in some patients with wild-type KRAS
status identiﬁed on their primary tumour. Moreover, other pre-
dictive factors need to be validated, such as v-raf murine sarcoma
viral oncogene homolog B1 (BRAF) mutations, phosphatidylinosi-
tide 3-kinases (PI3K) mutations, and loss of phosphatase and tensin
homologue (PTEN). These factors may  enable better selection of
patients for anti-EGFR drugs. These ﬁndings highlight the poten-
tial need for repeated biopsies along the therapeutic course, to
obtain the molecular signature of targeted lesions, and reﬁne
the predictive factors of anti-EGFR drugs and potentially other
treatments.
Cetuximab and panitumumab have demonstrated clinical activ-
ity in ﬁrst- and second-line treatment [7,8,31,32]. This raises the
question of re-challenge with anti-EGFR drugs beyond the sec-
ond line, in patients pretreated with anti-EGFR drugs. Recently,
a prospective phase II study investigated the rechallenge of
cetuximab-plus-irinotecan-based chemotherapy in 39 patients
who had previously experienced a clinical beneﬁt with the same
regimen, and then a progression. The results are encouraging, as
the overall response rate was 53.8%, the partial response rate was
48.7%, complete response rate was 5.1% and the stable disease rate
was 35.9%. Median progression-free survival was 6.6 months [38].
Patients could also be rechallenged with another anti-EGFR anti-
body. In a recently published single-arm phase II study, 20 patients
with prior progression on cetuximab were treated with panitu-
mumab. There was no objective response; 45% patients had a stable
disease. Median progression-free survival was 1.9 months and
median overall survival was  5.2 months [39]. However, the results
of a French institutional prospective study (PANERB study) have
recently been updated, including 106 patients with KRAS wild-
type tumours, progressing on cetuximab associated with irinotecan
and then treated with panitumumab. Forty-ﬁve percent of patients
had an objective response to the initial cetuximab-based therapy,
and 18% had an objective response to panitumumab. Among the
48 patients who had an initial response to cetuximab, 31% had a
response to panitumumab, and 16% had a stable disease. Among
the 28 patients who  initially had a resistance to cetuximab, 2
patients had an objective response to panitumumab, and 2 patients
had stable disease [40]. This question of anti-EGFR rechallenge is
thus controversial and further larger prospective trials are warr-
anted. Cetuximab resistance can be mediated by the activation of
alternative pathways [41], but another mechanism of resistance to
cetuximab has recently been unveiled. An acquired mutation of the
EGFR ectodomain was detected, preventing the binding of cetux-
imab to the receptor and conferring drug resistance. However, the
binding of panitumumab is not impaired. This mutation was  iden-
tiﬁed in 2 out of 10 patients progressing on cetuximab therapy.
One patient with the mutation responded to further panitumumab
therapy [42]. The knowledge of the mechanisms of drug resistance
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Table 2
Epidermal growth factor receptor inhibitor trials in third-line therapy.
Study
protocol
Number of
patients  in
third  line
or  more (%)
KRAS
status
Group Number of
patients
Median
overall
survival
HR (95% CI) Median
PFS
HR  (95% CI) Overall
response
rate (%)
Cetuximab studies:
Jonker  DJ et al. [9]
Karapetis  CS et al. [11]
C + BSC
versus BSC
alone
depending
on  KRAS
status
321 (81.5) WT KRAS C + BSC 117 9.5 months* 0.55
(0.41–0.74)
3.7
months*
0.40
(0.30–0.54)
12.8
BSC 113 4.8 months* 1.9
months*
0
M KRAS C + BSC 81 4.5 months 0.98
(0.7–1.37)
1.8 months 0.99
(0.73–1.35)
1.2
BSC 83 4.6 months 1.8 months 0
Cunningham  D et al., [12] C + I versus
C alone
261 (79) Not
evaluated
C  + I 218 8.6 months 0.91
(0.68–1.21)
4.1
months*
0.54
(0.42–0.71)
22.9
C 111 6.9 months 1.5
months*
10.8
Panitumumab studies:
Van  Cutsem E et al., [10]
Amado  RG et al., [18]
P + BSC
versus BSC
alone
depending
on  KRAS
status
270 (63.2) WT KRAS P + BSC 124 8.1 months 0.99
(0.75–1.29)
12.3
weeks*
0.45
(0.34–0.59)
17
BSC 119 7.6 months 7.3 weeks* 0
M KRAS P + BSC 84 4.9 months 1.02
(0.75–1.39)
7.4 weeks 0.99
(0.73–1.36)
0
BSC 100 4.4 months 7.3  weeks 0
Abbreviations: Nb: number; C: cetuximab; BSC: best supportive care; I: irinotecan; P: panitumumab; WT:  wild-type; M: mutated; OS: overall survival; HR: hazard ratio; PFS:
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* Statistically signiﬁcant results.
ould enable better selection of patients who may  beneﬁt from two
ines of anti-EGFR antibodies.
When cetuximab was evaluated in third-line therapy, previ-
us bevacizumab therapy was permitted, but a subgroup analysis
n this population has not been published. Fifty-eight consecu-
ive patients were included in a recently published report. Patients
ith advanced colorectal cancer were treated with cetuximab, with
r without prior anti-VEGF therapy. Patients with prior anti-VEGF
herapy had a signiﬁcantly lower disease-speciﬁc survival, com-
ared with naïve patients (9.1 months versus 4.9 months; P = 0.026;
R = 2.2; 95% CI 1.1 to 4.5, P = 0.03) [43]. In the randomized trial
nvestigating the combination of panitumumab with FOLFIRI in
econd-line therapy, a subgroup analysis investigated the effect of
 prior treatment with bevacizumab. Panitumumab signiﬁcantly
mproved PFS (HR = 0.77, 95% CI 0.61 to 0.96) in the 482 patients
ho did not receive bevacizumab in ﬁrst-line treatment, but the
ifference was not signiﬁcant in the 115 patients who received
evacizumab (HR = 0.71, 95% CI 0.45 to 1.13). However, this lack
f statistically signiﬁcant effect may  be related to a relatively low
umber of patients and a lack of power [8]. Prospective studies are
equired, since these results highlight the crucial need for clinical
rials evaluating multi-line treatments to identify the best thera-
eutic sequences.
.5.  Regorafenib, a new option
Regorafenib (Stivarga®) is an oral multi-targeted tyrosine kinase
nhibitor. The CORRECT trial randomized 760 patients to receive
egorafenib or placebo plus best supportive care, with an improved
verall survival as a primary endpoint. Patients had previously
ailed all approved standard therapies, including 5FU, oxalipla-
in, irinotecan, bevacizumab, and anti-EGFR drug in patients withrtial tumour response.
KRAS  wild-type cancers. Hazard ratio for overall survival was  0.77
(95% CI 0.64 to 0.94, P = 0.0052). Median overall survival was  6.4
months for regorafenib and 5.0 months for placebo. Hazard ratio for
progression-free survival was  0.49 (95% CI 0.42 to 0.58; P < 0.0001),
median progression-free survival was  1.9 months for regorafenib
and 1.7 months for placebo. Notably, regorafenib was associ-
ated with signiﬁcant adverse effects, mainly fatigue, hypertension,
hand–foot syndrome, diarrhoea and cutaneous rash. However,
these adverse effects were mostly manageable, and regorafenib
was associated with a maintained quality of life [44]. Regorafenib
was approved by the US Federal Drug Administration in September
2012. Regorafenib can be considered a new standard of care in
patients with chemotherapy-refractory disease, but should only be
discussed in patients in good condition, after information about the
potential beneﬁts and adverse effects of the treatment. The recom-
mended dose is 160 mg  (four 40 mg tablets) orally, once daily, with
a low-fat breakfast, for the ﬁrst 21 days of each 28-day cycle.
2.6.  Other anti-angiogenic therapies
Bevacizumab is a recombinant humanized monoclonal anti-
body that binds to and neutralizes vascular endothelial growth
factor (VEGF). In the ﬁrst- and second-line chemotherapy regi-
mens for metastatic colorectal cancer, this biological therapy
improves progression-free survival and overall survival when
combined with irinotecan plus LV/FU [4] and when combined
with oxaliplatin, ﬂuorouracil and leucovorin [6,45]. Recent studies
strongly support the concept of sustained VEGF inhibition in ﬁrst-
and second-line therapy [46,47]. However, there is no published
phase III trial investigating anti-VEGF therapies beyond second-line
treatment. In a single-arm phase II study, 339 patients progres-
sing after treatment with both oxaliplatin- and irinotecan-based
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hemotherapy regimens were treated using a combination of beva-
izumab, ﬂuorouracil and leucovorin. The response rate was  1%, the
rogression-free survival was 3.5 months and median overall sur-
ival was 9.1 months [48]. In another phase II study, bevacizumab
as evaluated in 48 heavily pretreated patients, after a ﬁrst-line
xaliplatin-based chemotherapy, a second-line irinotecan-based
hemotherapy and a third-line treatment with cetuximab plus
rinotecan. The response rate was 6.25%, the median time to pro-
ression was 3.5 months and the median overall survival was 7.7
onths. Eight patients had grade 3 or 4 haemorrhage and in one
atient a fatal outcome occurred after an urgent surgical proce-
ure. Importantly, none of the patients had previously received
evacizumab [49].
Brivanib  alaninate is a tyrosine kinase inhibitor targeting vas-
ular endothelial and ﬁbroblast growth factor receptors. A phase
II trial randomized 750 patients to receive cetuximab plus either
rivanib alaninate or placebo, and the results were presented
t the 2012 Gastrointestinal Cancers Symposium. Patients had
etastatic chemotherapy refractory K-RAS wild-type colorectal
ancer. Ninety-two percent of patients had received more than
 previous chemotherapy regimens and 41% had received prior
nti-VEGF therapy. Progression-free survival (5.0 months versus
.4 months, HR = 0.72; 95% CI 0.62 to 0.84; P < 0.0001) and response
ate (13.6% versus 7.2%, P = 0.004) were increased in the experi-
ental arm. However, median overall survival was  not statistically
mproved in the brevanib alaninate arm, compared with placebo
8.8 months versus 8.1 months, HR = 0.88; 95% CI 0.74 to 1.03;
 = 0.12) [50].
.7. Toxicity proﬁle of targeted agents
To select the most appropriate targeted therapy, it is impor-
ant to consider some expected toxicities and to discuss them
ith the patient. Some adverse effects can be observed with
ifferent therapies, such as fatigue, gastrointestinal effects (nau-
ea, constipation or diarrhoea) and haematological toxicities.
nti-EGFR drugs are well known to provide dermatological tox-
city (papulopustular rash, xerosis, desquamation, pruritus, hair
hange, paronychia). Skin toxicity can have a severe impact on
atients’ physical, psychological and social well-being and can
ead to treatment discontinuation, dose reduction and compli-
ations. Appropriate prophylaxis and therapeutic interventions
hould therefore be proposed to all patients treated with cetux-
mab or panitumumab [51]. In the CORRECT study, 54% of patients
ad grade 3/4 toxicities related to regorafenib. Most frequent grade
/4 adverse effects included hand-foot skin reaction (17%), fatigue
10%), diarrhoea (7%), hypertension (7%) [44]. Anti-VEGF agents
an lead to cardiovascular events such as hypertension, myocar-
ial infarction, venous and arterial thrombosis, and pulmonary
mbolism. Proteinuria should also be monitored during anti-VEGF
reatment. Comprehensive information should be given to the
atients, and the treatment should be adapted to the patient’s
omorbidities.
.8. Intra-arterial therapies for hepatic metastasis without
xtrahepatic disease
The  liver is the most common site for colorectal cancer metas-
ases. About 30% of patients with TNM stage III develop hepatic
etastases [52]. Normal liver vascularization is supplied 70% by the
ortal vein and 30% by hepatic arteries, while tumour lesions are
ainly supplied by hepatic arteries. Thus, intra-arterial therapies
ere investigated, aimed at delivering therapeutic agents directly
nto the liver and concentrating the drugs in the tumours. Different
ntra-arterial therapies have been developed.r Disease 46 (2014) 105– 112 109
2.9.  Transarterial chemoembolization
Transarterial  chemoembolization (TACE) is a procedure aimed
at delivering a high dose of chemotherapy directly into the liver,
through the arteries supplying the lesions. The chemotherapy
is associated with a blockage of arterial blood supply with an
embolic agent. The most common procedure consists of the injec-
tion of a chemotherapy agent emulsiﬁed with lipiodol, followed
by the injection of the embolic agent. More recently, drug eluting
beads (DEB) loaded with chemotherapy agents have been investi-
gated. This technique has been largely developed for the treatment
of hepatocellular carcinoma because they are hypervascularized
tumours. Few published studies evaluated TACE for metastatic
colorectal cancer beyond the second-line treatment.
Only one randomized study has been included in a Cochrane
review investigating the impact of TACE in liver metastases [53].
This study included 22 patients with colorectal liver metastases
treated with TACE and 20 treated with best supportive care. There
has been no signiﬁcant difference in the median survival of the
two groups (7.0 months in the TACE arm versus 7.9 months in
the control arm). However, few patients have been included, and
most patients had tumours involving more than 75% percent of
the liver [54]. In a recent large study, 121 patients were treated by
chemoembolization with mitomycin C, doxorubicin and cisplatin,
emulsiﬁed in ethiodized oil. Forty-six percent of patients previously
received two  or more lines of chemotherapy. Patients received a
median of 2 procedures. There was  a 2% response rate and a 41%
stable disease rate. Median survival from chemoembolization was
9 months. Median survival for patients previously treated by 0–1,
2, or more than 2 was 12, 11 and 6 months respectively [55].
Another  recently published study included 55 patients refrac-
tory to chemotherapy and targeted therapies, the majority having
failed to respond to 5FU, irinotecan, oxaliplatin, bevacizumab and
anti-EGFR drugs. Patients were treated with a median of 2 ses-
sions of TACE with irinotecan-preloaded DEB (DEBIRI). The median
progression-free survival was 11 months, the overall survival 19
months, and the response rate was 75% at 12 months [56]. In
another prospective study, 85 patients were included to receive
a DEBIRI therapy after one or two lines of chemotherapy. Fifty
patients had received two  lines of chemotherapy. Patients received
a median of 2.2 (range 1 to 4) procedures. The response rate was 78%
at 3 months. The median progression-free survival was  8 months
and the median overall survival was 25 months [57].
2.10.  Hepatic artery infusion
Hepatic  artery infusion (HAI) consists of a direct administra-
tion of chemotherapy, through a catheter placed in the hepatic
artery. Port-catheters can be surgically implanted, or percuta-
neously, most commonly through the femoral artery. The catheter
tip can be placed in the gastroduodenal artery and the gastroduo-
denal artery is then embolized. The catheter is perforated with a
side hole placed to enable infusion into the hepatic artery (Fig. 1A).
To prevent extrahepatic infusion, the right gastric artery and other
accessory branches to extrahepatic destinations are embolized. The
catheter is connected to a subcutaneous port to allow easy access
and repeated administrations (Fig. 1B). By using the transarterial
route of administration, a more than 10-fold increase in drug con-
centration within the liver can be achieved, compared with that
achieved through the intravenous route, with limited systemic
side effects [58]. Floxuridine, 5-ﬂuorodeoxyuridine, oxaliplatin and
mitomycin-C are commonly used. A clinical study evaluating HAI in
third-line therapy was recently published. Forty-four patients who
had previously received a median of 2 therapies, were included,
and 28 patients (63%) had received both oxaliplatin and irinote-
can. There were treated by HAI of oxaliplatin (100 mg/m2 over 2 h),
110 F.  Foubert et al. / Digestive and Liver Disease 46 (2014) 105– 112
Fig. 1. Implantation of an intrahepatic catheter for hepatic artery infusions. (A) The catheter tip is placed in the gastro-duodenal artery with coils around it. The side hole is
located  in the common hepatic artery for the perfusion. (a) Diagram. (b) Routine follow-up angiography performed with contrast medium injected through an arterial port
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ourtesy  of Dr Frédéric Deschamps, Institut Gustave Roussy, Villejuif, France.
ombined with intravenous leucovorin and 5 ﬂuorouracil (LV5FU2
egimen), every 2 weeks. Median progression-free survival and
verall survival were 7 and 16 months respectively. Twelve of the
8 patients refractory to both oxaliplatin and irinotecan obtained a
artial response (43%) [59]. There is no controlled trial in third-line
herapy or beyond evaluating HAI.
.11. Radioembolization
The  radioembolization procedure is quite similar to that of
hemoembolization, but the delivery device is a radioactive parti-
le, and for hepatic metastases of colorectal cancer, this radioactive
article is microspheres of yttrium 90, a radioisotope with a half-
ife of 64.1 h, pure emitter of  particles with an average energy
f 0.94 MeV  and a mean path in tissue of 2.5 mm.  The micro-
pheres are too big to pass through to the venous circulation, but
an preferentially reach the tumours vascularised by the arterial
ystem [60]. A preliminary angiogram must be performed to deter-
ine the arterial supply of the liver. The gastroduodenal artery,
he right gastric artery and any extra-hepatic branch originating
rom the hepatic artery must be embolized with coils to prevent
ttrium 90 from reﬂuxing to the stomach and duodenum. The main
ide effect reported is gastrointestinal ulcer, mainly due to unrec-
gnized arteries supplying the gastrointestinal tract. In a study
ublished in 2009 on radioembolization with yttrium 90, 28 of
he 72 patients included had received the three major chemother-
py agents (5-ﬂuorouracil, irinotecan and oxaliplatin) before the
adioembolization. Most of them had liver-conﬁned disease. There
as a 40.3% response rate and a 14.5-month overall survival, with
cceptable toxicities [61]. Another trial evaluated retrospectively41  patients with colorectal liver metastases. Four of them had other
metastatic involvement. They had all previously received and failed
with standard ﬁrst-line FOLFOX, second-line FOLFIRI and third-line
chemotherapies. Nineteen patients (46.3%) had a response (2 had
a complete response and 17 had a partial response), the median
progression-free survival was  9.2 months and the median survival
time was  11.6 months. One patient had grade 4 hepatic failure,
probably due to radiation-induced hepatitis [62].
Some studies compared radioembolization with other treat-
ments in patients previously treated with chemotherapy. As a sal-
vage treatment for liver-dominant colorectal metastatic adenocar-
cinoma, no difference was  observed between chemoembolization
with cisplatin, doxorubicin and mitomycin C and radioemboliza-
tion, as median survival was 7.7 months and 6.9 months respec-
tively (P = 0.27). These results were obtained in a case-controlled
study including 36 patients who had progressed after previous
lines of systemic chemotherapy that included the FOLFOX regimen,
the FOLFIRI regimen, capecitabine, bevacizumab and cetuximab
[63]. In a phase III prospective multicenter randomized trial, intra-
venous ﬂuorouracil alone was compared with the combination
of radioembolization plus intravenous ﬂuorouracil, in 46 patients
with liver-limited metastatic colorectal cancer, refractory to stan-
dard chemotherapy (FU, oxaliplatin and irinotecan). The overall
response rate was low (9.5% in the combined therapy group versus
0% in the 5FU group), but the median time to progression was  sta-
tistically longer in the group that received radioembolization (4.5
months versus 2.1 months in the 5FU alone group, HR = 0.51; 95% CI
0.28 to 0.94; P = 0.03). There was  no signiﬁcant difference in median
overall survival between the treatment arms, likely because cross-
over was permitted and 70% of patients in the FU-only arm received
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urther therapy, including radioembolization [64]. Radioemboliza-
ion should be considered a palliative option for the treatment of
etastatic colorectal cancer, but for selected patients with liver-
imited metastases. However, the technique is limited to only a few
entres. Further controlled trials are needed to determine if this
herapy should be used earlier in ﬁrst- or second-line treatment.
.  Conclusion
Patients with unresectable metastatic colorectal cancers can
e candidates for multiple lines of therapy. Even in previously
eavily treated patients, different options should be considered.
n patients with KRAS wild-type tumours, anti-EGFR must be con-
idered.
The impact of panitumumab in patients pretreated with cetux-
mab should be further investigated. Chemotherapy can still be an
ption. If the patient has not already received all major chemother-
py agents, the never-used agent should be considered. Moreover,
 drug previously used with a good response could be reintroduced.
Regorafenib, a multi-kinase inhibitor, has recently been
pproved by the US FDA and is now standard in patients who
ave failed all other standard therapies. In the case of hepatic
etastasis, intra-arterial therapies should be discussed. Promising
esults have been reported with transarterial chemoembolization,
epatic artery infusion and radioembolization, but these tech-
iques, especially HAI and radioembolization, are limited to a few
xpert centres only, and larger trials should support their interest.
ifferent lines of intra-arterial therapy could be considered, and
he best sequences should be identiﬁed.
Patients able and willing to receive further therapy should ﬁrst
e considered for inclusion in clinical trials. Nevertheless, many
ptions can be discussed. The choice of a treatment depends on pre-
iously used therapies, on the patient and on the tumour biology. A
ultiline strategy based on both the patient and the cancer should
e anticipated. Strategic trials are urgently needed to determine
he best therapeutic sequences.
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